The last several years have seen significant growth in the number and utilization of specialty drugs. Cancer immunotherapy, in particular, has experienced growth in the

This report from the National Alliance of Healthcare Purchasers offers insights and a framework for employers on how they can better influence how drugs are

Denise Giambalvo, MBGH Vice President, shares five actions employers can take to create savings for their pharmacy benefits plan and plan members. Read More

Biosimilars, which at the most simplistic level can be thought of as a type of generic option for a biologic, offer an opportunity to help

A small, yet rapidly growing segment of commercially insured US patients have drug costs of more than $250,000 each year, and this group could account

Advancement in the treatment of a wide variety of cancers has resulted from significant innovations in the pharmaceutical pipeline. These developments present significant challenges to payers due

The problem of drug pricing is not the brainchild of a Pharma cabal of Dr. Evils. The problem is a cabal of public policies virtually

Action steps employers can take to influence change that will ultimately lead to more options for employees and their dependents who are dealing with diseases like

The insurance giant is leaving its current PBM in 2020, and if it can accomplish better transparency and lower prices, the savings could potentially be

Employers only have a minimal understanding of their current pharmacy benefit manager contracts. Read full article here